Sickle cell anemia in Northern Israel: Screening and prevention

Israel Medical Association Journal

Volumn 11, Issue 4, 2009, Pages 229-234

  Koren, Ariel ^a,b   Zalman, Lucia ^a   Palmor, Haya ^a   Zarnir, Ronit Bril ^a   Levin, Carina ^a,b   Openheim, Ariella ^c   Daniel Spiegel, Etty ^a   Shalev, Stavit ^a,b   Filon, Dvora ^c  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Prevention; Screening; Sickle cell anemia

Indexed keywords

HAPTOGLOBIN O; HEMOGLOBIN; HEMOGLOBIN C; HEMOGLOBIN D; HEMOGLOBIN S; UNCLASSIFIED DRUG;

ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; FETUS; GESTATIONAL AGE; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; ISRAEL; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PREVENTIVE HEALTH SERVICE; PROGENY; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SCREENING TEST; SICKLE CELL ANEMIA; THERAPEUTIC ABORTION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BETA-GLOBULINS; BETA-THALASSEMIA; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HEMOGLOBIN, SICKLE; HUMANS; ISRAEL; PREGNANCY; PRENATAL DIAGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 67549134944     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Goldberg A, Varsano D, Lerman M, Kaufman S. A new focus of the sickle cell gene in Israel. Harefuah 1983; 104: 9-10 (Hebrew).
2. Kirschmann C, Shalmon L, Goshen Y, Zaizov R. Genetic characterization of sickle-cell anemia in Israeli Arabs. Harefuah 1987; 113: 201-4 (Hebrew).
3. Moses WM, Y. Levin, S. Sickle cell disease in Israel. Harefuah 1956; 51: 255-62 (Hebrew).
4. Filon D, Oron V, Krichevski S, et al. Diversity of beta-globin mutations in Israeli ethnic groups reflects recent historic events. Am J Hum Genet 1994; 54: 836-43.
5. Zlotogora J, Hujerat Y, Zalman L, et al. Origin and expansion of four different beta globin mutations in a single Arab village. Am J Hum Biol 2005; 17: 659-61.
6. Golik T, Reif S. Sickle cell anemia - old disease, new patients. Harefuah 2007; 146: 335-6, 408 (Hebrew).
7. Koren A, Zalman L, Palmor H, et al. The prevention programs for beta thalassemia in the Jezreel and Eiron valleys: results of fifteen years experience. Harefuah 2002; 141: 938-43, 1210 (Hebrew).
8. Roth EF, Jr., Rachmilewitz EH, Schifter A, Nagel RL. Benign sickle cell anemia in Israeli-Arabs with high red cell 2,3 diphosphoglycerate. Acta Haematol 1978; 59: 237-45.
9. Loukopoulos D, Hadji A, Papadakis M, et al. Prenatal diagnosis of thalassemia and of the sickle cell syndromes in Greece. Ann NY Acad Sci 1990; 612: 226-36.
10. Giordano PC, Plancke A, Van Meir CA, et al. Carrier diagnostics and prevention of hemoglobinopathies in early pregnancy in The Netherlands: a pilot study. Prenat Diagn 2006; 26: 719-24.
11. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med 2007; 9: 372-7.
12. Petrou M, Brugiatelli M, Ward RH, Modell B. Factors affecting the uptake of prenatal diagnosis for sickle cell disease. J Med Genet 1992; 29: 820-3.
13. Alexandre L, Keclard L, Romana M, et al. Efficiency of prenatal counselling for sickle cell disease in Guadeloupe. Genet Couns 1997; 8: 25-32.
14. Colah R, Surve R, Nadkarni A, et al. Prenatal diagnosis of sickle syndromes in India: dilemmas in counselling. Prenat Diagn 2005; 25: 345-9.
15. Ayesh SK, Al-Sharef WA, Nassar SM, Thawabteh NA, Abu-Libdeh BY. Prenatal diagnosis of beta-thalassemia in the West Bank and Gaza. Saudi Med J 2005; 26: 1771-6.
16. Kagu MB, Abjah UA, Ahmed SG. Awareness and acceptability of prenatal diagnosis of sickle cell anaemia among health professionals and students in North Eastern Nigeria. Niger J Med 2004; 13: 48-51.
17. de Montalembert M, Guilloud-Bataille M, Ducros A, et al. Implications of prenatal diagnosis of sickle cell disease. Genet Couns 1996; 7: 9-15.
18. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001; 357: 680-3.
19. Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-44.
20. Kmietowicz Z. Sickle cell screening makes genetic counselling everybody's business. BMJ 2006; 332: 570.
21. Modell BA, MN. Guidelines for screening for haemoglobin disorders: services specifications for low and high prevalence DHA's. Ethnicity and Health: Reviews of Literature and Guidance for Purchasers in the Areas of Cardiovascular Disease, Mental Health and Haemoglobinopathies. York, UK: University of York, NHS Centre for Reviews and Dissemination CRD Report 5, Part 4; 1996: 127-224.
22. Cronin EK, Normand C, Henthorn JS, Graham V, Davies SC. Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. Br J Obstet Gynaecol 2000; 107: 486-91.